Global Cancer Diagnostics Service 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR032504148

Publication Date:

March 7, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Software [2]

IT Services [3]

Computing & Electronics [4]

Description:

The global Cancer Diagnostics Service market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Cancer Diagnostics Service market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cancer Diagnostics Service market size and forecasts, in consumption value ($ Million), 2020-2031
Global Cancer Diagnostics Service market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Cancer Diagnostics Service market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Cancer Diagnostics Service market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Cancer Diagnostics Service
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Cancer Diagnostics Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Illumina, BGI Genomics Co.,Ltd., Agilent Technologies, Macrogen, Pacific Biosciences, Abbott, QIAGEN, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Applied DNA Sciences, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Cancer Diagnostics Service market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Breast Cancer
Blood Cancer
Lung Cancer
Colorectal Cancer
Ovarian Cancer
Others
麻豆原创 segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Laboratories
Others
麻豆原创 segment by players, this report covers
Illumina
BGI Genomics Co.,Ltd.
Agilent Technologies
Macrogen
Pacific Biosciences
Abbott
QIAGEN
Siemens Healthcare GmbH
Thermo Fisher Scientific, Inc.
Applied DNA Sciences
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Cancer Diagnostics Service product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Cancer Diagnostics Service, with revenue, gross margin, and global market share of Cancer Diagnostics Service from 2020 to 2025.
Chapter 3, the Cancer Diagnostics Service competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Cancer Diagnostics Service market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Cancer Diagnostics Service.
Chapter 13, to describe Cancer Diagnostics Service research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Cancer Diagnostics Service by Type
1.3.1 Overview: Global Cancer Diagnostics Service 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Cancer Diagnostics Service Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Breast Cancer
1.3.4 Blood Cancer
1.3.5 Lung Cancer
1.3.6 Colorectal Cancer
1.3.7 Ovarian Cancer
1.3.8 Others
1.4 Global Cancer Diagnostics Service 麻豆原创 by Application
1.4.1 Overview: Global Cancer Diagnostics Service 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospitals
1.4.3 Ambulatory Surgical Centers
1.4.4 Diagnostic Laboratories
1.4.5 Others
1.5 Global Cancer Diagnostics Service 麻豆原创 Size & Forecast
1.6 Global Cancer Diagnostics Service 麻豆原创 Size and Forecast by Region
1.6.1 Global Cancer Diagnostics Service 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Cancer Diagnostics Service 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Cancer Diagnostics Service 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Cancer Diagnostics Service 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Cancer Diagnostics Service 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Cancer Diagnostics Service 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Cancer Diagnostics Service 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Illumina
2.1.1 Illumina Details
2.1.2 Illumina Major Business
2.1.3 Illumina Cancer Diagnostics Service Product and Solutions
2.1.4 Illumina Cancer Diagnostics Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Illumina Recent Developments and Future Plans
2.2 BGI Genomics Co.,Ltd.
2.2.1 BGI Genomics Co.,Ltd. Details
2.2.2 BGI Genomics Co.,Ltd. Major Business
2.2.3 BGI Genomics Co.,Ltd. Cancer Diagnostics Service Product and Solutions
2.2.4 BGI Genomics Co.,Ltd. Cancer Diagnostics Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 BGI Genomics Co.,Ltd. Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Cancer Diagnostics Service Product and Solutions
2.3.4 Agilent Technologies Cancer Diagnostics Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 Macrogen
2.4.1 Macrogen Details
2.4.2 Macrogen Major Business
2.4.3 Macrogen Cancer Diagnostics Service Product and Solutions
2.4.4 Macrogen Cancer Diagnostics Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Macrogen Recent Developments and Future Plans
2.5 Pacific Biosciences
2.5.1 Pacific Biosciences Details
2.5.2 Pacific Biosciences Major Business
2.5.3 Pacific Biosciences Cancer Diagnostics Service Product and Solutions
2.5.4 Pacific Biosciences Cancer Diagnostics Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Pacific Biosciences Recent Developments and Future Plans
2.6 Abbott
2.6.1 Abbott Details
2.6.2 Abbott Major Business
2.6.3 Abbott Cancer Diagnostics Service Product and Solutions
2.6.4 Abbott Cancer Diagnostics Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Abbott Recent Developments and Future Plans
2.7 QIAGEN
2.7.1 QIAGEN Details
2.7.2 QIAGEN Major Business
2.7.3 QIAGEN Cancer Diagnostics Service Product and Solutions
2.7.4 QIAGEN Cancer Diagnostics Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 QIAGEN Recent Developments and Future Plans
2.8 Siemens Healthcare GmbH
2.8.1 Siemens Healthcare GmbH Details
2.8.2 Siemens Healthcare GmbH Major Business
2.8.3 Siemens Healthcare GmbH Cancer Diagnostics Service Product and Solutions
2.8.4 Siemens Healthcare GmbH Cancer Diagnostics Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Siemens Healthcare GmbH Recent Developments and Future Plans
2.9 Thermo Fisher Scientific, Inc.
2.9.1 Thermo Fisher Scientific, Inc. Details
2.9.2 Thermo Fisher Scientific, Inc. Major Business
2.9.3 Thermo Fisher Scientific, Inc. Cancer Diagnostics Service Product and Solutions
2.9.4 Thermo Fisher Scientific, Inc. Cancer Diagnostics Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Thermo Fisher Scientific, Inc. Recent Developments and Future Plans
2.10 Applied DNA Sciences
2.10.1 Applied DNA Sciences Details
2.10.2 Applied DNA Sciences Major Business
2.10.3 Applied DNA Sciences Cancer Diagnostics Service Product and Solutions
2.10.4 Applied DNA Sciences Cancer Diagnostics Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Applied DNA Sciences Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Cancer Diagnostics Service Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Cancer Diagnostics Service by Company Revenue
3.2.2 Top 3 Cancer Diagnostics Service Players 麻豆原创 Share in 2024
3.2.3 Top 6 Cancer Diagnostics Service Players 麻豆原创 Share in 2024
3.3 Cancer Diagnostics Service 麻豆原创: Overall Company Footprint Analysis
3.3.1 Cancer Diagnostics Service 麻豆原创: Region Footprint
3.3.2 Cancer Diagnostics Service 麻豆原创: Company Product Type Footprint
3.3.3 Cancer Diagnostics Service 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Cancer Diagnostics Service Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Cancer Diagnostics Service 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Cancer Diagnostics Service Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Cancer Diagnostics Service 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Cancer Diagnostics Service Consumption Value by Type (2020-2031)
6.2 North America Cancer Diagnostics Service 麻豆原创 Size by Application (2020-2031)
6.3 North America Cancer Diagnostics Service 麻豆原创 Size by Country
6.3.1 North America Cancer Diagnostics Service Consumption Value by Country (2020-2031)
6.3.2 United States Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Cancer Diagnostics Service Consumption Value by Type (2020-2031)
7.2 Europe Cancer Diagnostics Service Consumption Value by Application (2020-2031)
7.3 Europe Cancer Diagnostics Service 麻豆原创 Size by Country
7.3.1 Europe Cancer Diagnostics Service Consumption Value by Country (2020-2031)
7.3.2 Germany Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Cancer Diagnostics Service Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Cancer Diagnostics Service Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Cancer Diagnostics Service 麻豆原创 Size by Region
8.3.1 Asia-Pacific Cancer Diagnostics Service Consumption Value by Region (2020-2031)
8.3.2 China Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Cancer Diagnostics Service Consumption Value by Type (2020-2031)
9.2 South America Cancer Diagnostics Service Consumption Value by Application (2020-2031)
9.3 South America Cancer Diagnostics Service 麻豆原创 Size by Country
9.3.1 South America Cancer Diagnostics Service Consumption Value by Country (2020-2031)
9.3.2 Brazil Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Cancer Diagnostics Service Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Cancer Diagnostics Service Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Cancer Diagnostics Service 麻豆原创 Size by Country
10.3.1 Middle East & Africa Cancer Diagnostics Service Consumption Value by Country (2020-2031)
10.3.2 Turkey Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Cancer Diagnostics Service 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Cancer Diagnostics Service 麻豆原创 Drivers
11.2 Cancer Diagnostics Service 麻豆原创 Restraints
11.3 Cancer Diagnostics Service Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Cancer Diagnostics Service Industry Chain
12.2 Cancer Diagnostics Service Upstream Analysis
12.3 Cancer Diagnostics Service Midstream Analysis
12.4 Cancer Diagnostics Service Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Illumina
BGI Genomics Co.,Ltd.
Agilent Technologies
Macrogen
Pacific Biosciences
Abbott
QIAGEN
Siemens Healthcare GmbH
Thermo Fisher Scientific, Inc.
Applied DNA Sciences

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.